Logo image of SEPN

SEPTERNA INC (SEPN) Stock Fundamental Analysis

USA - NASDAQ:SEPN - US81734D1046 - Common Stock

16 USD
+0.3 (+1.91%)
Last: 9/22/2025, 9:05:31 PM
16 USD
0 (0%)
After Hours: 9/22/2025, 9:05:31 PM
Fundamental Rating

3

Overall SEPN gets a fundamental rating of 3 out of 10. We evaluated SEPN against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for SEPN as it has an excellent financial health rating, but there are worries on the profitability. SEPN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SEPN had negative earnings in the past year.
In the past year SEPN has reported a negative cash flow from operations.
SEPN Yearly Net Income VS EBIT VS OCF VS FCFSEPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -19.17%, SEPN is doing good in the industry, outperforming 61.22% of the companies in the same industry.
SEPN has a better Return On Equity (-20.83%) than 67.35% of its industry peers.
Industry RankSector Rank
ROA -19.17%
ROE -20.83%
ROIC N/A
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEPN Yearly ROA, ROE, ROICSEPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

SEPN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEPN Yearly Profit, Operating, Gross MarginsSEPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SEPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SEPN has more shares outstanding
SEPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SEPN Yearly Shares OutstandingSEPN Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
SEPN Yearly Total Debt VS Total AssetsSEPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

SEPN has an Altman-Z score of 11.53. This indicates that SEPN is financially healthy and has little risk of bankruptcy at the moment.
SEPN's Altman-Z score of 11.53 is amongst the best of the industry. SEPN outperforms 86.73% of its industry peers.
There is no outstanding debt for SEPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.53
ROIC/WACCN/A
WACC9.8%
SEPN Yearly LT Debt VS Equity VS FCFSEPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

SEPN has a Current Ratio of 27.77. This indicates that SEPN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SEPN (27.77) is better than 97.45% of its industry peers.
SEPN has a Quick Ratio of 27.77. This indicates that SEPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 27.77, SEPN belongs to the top of the industry, outperforming 97.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 27.77
Quick Ratio 27.77
SEPN Yearly Current Assets VS Current LiabilitesSEPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SEPN have decreased strongly by -53868.89% in the last year.
The Revenue has grown by 611.92% in the past year. This is a very strong growth!
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.82%
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.68%

3.2 Future

The Earnings Per Share is expected to grow by 17.27% on average over the next years. This is quite good.
Based on estimates for the next years, SEPN will show a very strong growth in Revenue. The Revenue will grow by 264.40% on average per year.
EPS Next Y100.05%
EPS Next 2Y31.05%
EPS Next 3Y17.27%
EPS Next 5YN/A
Revenue Next Year10618.3%
Revenue Next 2Y666.69%
Revenue Next 3Y264.4%
Revenue Next 5YN/A

3.3 Evolution

SEPN Yearly Revenue VS EstimatesSEPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 20M 40M 60M
SEPN Yearly EPS VS EstimatesSEPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SEPN. In the last year negative earnings were reported.
Also next year SEPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEPN Price Earnings VS Forward Price EarningsSEPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEPN Per share dataSEPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as SEPN's earnings are expected to grow with 17.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.05%
EPS Next 3Y17.27%

More info and screens

0

5. Dividend

5.1 Amount

SEPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEPTERNA INC

NASDAQ:SEPN (9/22/2025, 9:05:31 PM)

After market: 16 0 (0%)

16

+0.3 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-20 2025-11-20
Inst Owners105.6%
Inst Owner Change-1.79%
Ins Owners2.64%
Ins Owner Change1.44%
Market Cap713.44M
Analysts80
Price Target23.46 (46.63%)
Short Float %7.21%
Short Ratio13.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-85.59%
Min EPS beat(2)-163.84%
Max EPS beat(2)-7.35%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.87%
Min Revenue beat(2)-98.97%
Max Revenue beat(2)114.71%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.05%
EPS NQ rev (1m)12.15%
EPS NQ rev (3m)261.22%
EPS NY rev (1m)0%
EPS NY rev (3m)100.47%
Revenue NQ rev (1m)23.53%
Revenue NQ rev (3m)46566.7%
Revenue NY rev (1m)2.34%
Revenue NY rev (3m)18648.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 982.7
P/FCF N/A
P/OCF N/A
P/B 1.7
P/tB 1.7
EV/EBITDA N/A
EPS(TTM)-10.08
EYN/A
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS0.02
BVpS9.42
TBVpS9.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.17%
ROE -20.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.89%
Cap/Sales 224.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.77
Quick Ratio 27.77
Altman-Z 11.53
F-Score4
WACC9.8%
ROIC/WACCN/A
Cap/Depr(3y)237.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.82%
EPS Next Y100.05%
EPS Next 2Y31.05%
EPS Next 3Y17.27%
EPS Next 5YN/A
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.68%
Revenue Next Year10618.3%
Revenue Next 2Y666.69%
Revenue Next 3Y264.4%
Revenue Next 5YN/A
EBIT growth 1Y-77.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.99%
EBIT Next 3Y-35.61%
EBIT Next 5YN/A
FCF growth 1Y-67.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.24%
OCF growth 3YN/A
OCF growth 5YN/A